Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Antibody–drug conjugates (ADCs) and next-generation antibody conjugates have rapidly become a leading class of targeted biologics, combining the molecular specificity of antibodies with highly potent payloads. With multiple global approvals and a fast-expanding clinical pipeline, ADCs are reshaping therapeutic strategies across oncology and immune-related diseases.
Unlike conventional monoclonal antibodies, ADCs are inherently multi-component systems. Their clinical performance is governed by the integrated control of antibody engineering, linker–payload chemistry, conjugation strategy, and manufacturing process consistency. Small variations in conjugation or process conditions can significantly affect drug-to-antibody ratio (DAR), stability, pharmacokinetics, and safety.
As the field advances toward site-specific conjugation technologies and next-generation antibody conjugates, regulatory expectations increasingly emphasize process understanding, critical quality attribute control, and CMC readiness. Successful ADC translation, therefore, depends on early, end-to-end integration of biologics, chemistry, analytics, and GMP-aligned manufacturing—making an experienced, cross-disciplinary CDMO partner essential.
Creative Biogene provides an integrated ADC platform covering antibody generation, linker–payload development, bioconjugation process engineering, GMP manufacturing, and pharmacodynamic evaluation. Our platform is designed to support both classical ADCs and emerging conjugate modalities within a unified quality and regulatory framework.
Creative Biogene offers end-to-end ADC CDMO services from payload–linker synthesis to drug substance and drug product manufacturing, enabling seamless technology transfer and reduced development risk across discovery, IND-enabling, clinical, and commercial stages.
CMC & GMP Manufacturing

Linker–Payload Platform

Antibody & Cell Platform

Analytics & Translation

Conjugation Platform

Our ADC platform integrates multidisciplinary expertise across chemistry, biologics, analytics and regulatory sciences.
High-quality conjugates start with developable antibodies. Our biologics platform integrates antibody engineering with downstream conjugation strategy design.
Capabilities

Creative Biogene provides in-house linker–payload development and high-potency manufacturing infrastructure to support scalable ADC production.
capabilities

Our conjugation platform is designed for reproducibility, DAR control, and regulatory-ready scale-up.
Process and manufacturing features:

Creative Biogene operates a dedicated ADC analytical platform aligned with ICH Q6B, Q1A–Q1E and emerging FDA / EMA ADC guidance.
Molecular Characterization
Impurity & Safety Profiling
Sterility & Container Integrity
Stability & Formulation
| Test Category | Capability |
| Intact mass analysis | LC-MS, accuracy < 5 ppm |
| DAR determination | HIC, RP-LC, LC-MS (±0.2 precision) |
| Conjugation site mapping | LC-MS/MS |
| Aggregation & purity | SEC-HPLC, CE-SDS |
| Higher-order structure | CD, FT-IR, DSC (Tm ±0.5 °C) |
| Category | Control Capability |
| Free payload | LOQ ≤ 0.05% |
| Genotoxic impurities | ICH M7 compliant, LC-MS/MS |
| Residual solvents | USP<467>, GC-MS |
| Unconjugated antibody | HIC ≤ 1% |
| Test | Capability |
| Endotoxin | LOD ≤ 0.01 EU/mL |
| Sterility | Isolator-based sterility testing |
| CCI testing | Vacuum decay, ≥ 1 μm sensitivity |
| Study Type | Capability |
| Forced degradation | Oxidation, heat, pH, light, freeze–thaw |
| Long-term stability | 2–8 °C, up to 24 months |
| Formulation | Liquid and lyophilized |
| Transport simulation | Agitation and vibration stress |
Creative Biogene offers dedicated development and manufacturing platforms tailored to different conjugate modalities and development stages.
With integrated chemistry, biologics, analytics, and regulatory infrastructure, Creative Biogene delivers development-ready conjugates with controlled quality, scalable processes, and regulatory confidence. Our ADC CDMO platform supports flexible collaboration models:
Programs may enter at any development stage while maintaining continuity toward GMP manufacturing and regulatory submission. Contact our ADC CDMO team to discuss your program requirements and development strategy.